Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

DelveInsight's TYK2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024. Product sales grew 9%, driven by 13% volume g ...

Squibb Coffee's new European-inspired cafe brings wine, cheese, small plates and coffee together in one space.

Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.